Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus

Heng, Wen Tzuen; Lim, Hui Xuan; Tan, Kuan Onn; Poh, Chit Laa

doi:10.1007/s11095-023-03540-x

Cited by 9 publications

(5 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among various polymeric NPs, PLGA NPs are the most extensively investigated as vaccine carriers, largely due to their US FDA approval and licensing for medical applications [73,[153][154][155]]. An early study has shown that PLGA NPs loaded with indocyanine green (ICG) and a toll-like-receptor-7 agonist (R837), combined with photothermal therapy (PTT), can elicit a greater anti-tumor immune response compared to traditional adjuvants [156].…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

“…NPs have been studied by several research groups with great success in the field of vaccination [ 51 , 67 – 69 ]. Despite well-documented research on nanovaccine synthesis and applications, the majority of which discusses their possible use in treating diseases, infections, and other health issues [ 38 , 70 – 73 ], there are few reports on nanovaccines in cancer immunotherapy [ 74 , 75 ]. For example, Bhardwaj et al .…”

Section: Introductionmentioning

confidence: 99%

“…NPs have been studied by several research groups with great success in the field of vaccination [51,[67][68][69]. Despite well-documented research on nanovaccine synthesis and applications, the majority of which discusses their possible use in treating diseases, infections, and other health issues [38,[70][71][72][73], there are few reports on nanovaccines in cancer immunotherapy [74,75]. For example, Bhardwaj et al summarized the use of nanovaccines in the treatment of infectious and non-infectious diseases, such as malaria, tuberculosis, human immunodeficiency virus (HIV)/AIDS, influenza, and cancer [70].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Sun,

Zhao,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

Despite recent advancements in cancer treatment, this disease still poses a serious threat to public health. Vaccines play an important role in preventing illness by preparing the body's adaptive and innate immune responses to combat diseases. As our understanding of malignancies and their connection to the immune system improves, there has been a growing interest in priming the immune system to fight malignancies more effectively and comprehensively. One promising approach involves utilizing nanoparticle systems for antigen delivery, which has been shown to potentiate immune responses as vaccines and/or adjuvants. In this review, we comprehensively summarized the immunological mechanisms of cancer vaccines while focusing specifically on the recent applications of various types of nanoparticles in the field of cancer immunotherapy. By exploring these recent breakthroughs, we hope to identify significant challenges and obstacles in making nanoparticle-based vaccines and adjuvants feasible for clinical application. This review serves to assess recent breakthroughs in nanoparticle-based cancer vaccinations and shed light on their prospects and potential barriers. By doing so, we aim to inspire future immunotherapies for cancer that harness the potential of nanotechnology to deliver more effective and targeted treatments. Graphical abstract

show abstract

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Sun,

Zhao,

et al. 2024

J Nanobiotechnol

View full text Add to dashboard Cite

show abstract

“…The dawn of personalised medicine allows treatments to be tailored based on the tumor's genetic makeup, enhancing the efficacy of MOAP-1 targeting. Advanced drug delivery systems, such as oncolytic adenoviruses or nanoparticles, promise enhanced delivery of MOAP-1 inhibitors directly to tumor sites, minimising off-target effects and bolstering therapeutic outcomes [23,66] . Moreover, the regular monitoring of a tumor's response to treatment can herald early signs of resistance development, allowing for timely therapeutic recalibrations [67,68] .…”

Section: Future Perspectivesmentioning

confidence: 99%

Therapeutic Targeting of MOAP-1 in Cancer: A Systematic Review of Current Approaches and Future Directions

Koong,

Look,

Abdullah

et al. 2023

Prog Micobes Mol Biol

View full text Add to dashboard Cite

The Modulator of Apoptosis 1 (MOAP-1) protein, a crucial regulator of apoptosis, has recently attracted considerable interest in oncology research. Its potential as a therapeutic target in bladder, breast, and non-small cell lung cancer (NSCLC) offers intriguing new therapeutic approaches. This comprehensive review consolidated work on MOAP-1's role in cancer biology, notably as a therapeutic target. A systematic review was conducted by searching digital databases for studies. Based on inclusion and exclusion criteria, ten articles were thoroughly assessed. Emerging evidence links MOAP-1 to bladder cancer chemosensitivity and MOAP-1-dependent chemosensitization of breast cancer mediated by phenylquinazoline derivatives. In addition, apoptosis in breast cancer cells was induced by α-mangostin, a potential therapeutic drug targeting MOAP-1 and BCL-XL interaction. Studies showed MOAP-1's importance in NSCLC, with its upregulation in the cancer cells as a potential treatment. This review also highlights the role of miR-25 as a cellular regulator of MOAP-1 and its implication for MOAP-1-mediated therapeutics. The intricate control of MOAP-1 in cancer highlights the need for more research to understand its function and regulation across cancer types completely. MOAP-1's tumor suppressor activity suggests it could be a therapeutic target, as evidenced by current research findings, which is likely to spur further research into MOAP-1-targeted cancer treatments. This systematic review fills a gap in the literature by bringing together a variety of study findings to promote a deeper understanding of MOAP-1 and its therapeutic potential.

show abstract

“…Controlled-release poly (lactic-co-glycolic acid) (PLGA) microparticles loaded with synthetic peptides corresponding to immunogenic epitopes found in pathogens [ 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 ] and tumor cells [ 37 , 38 , 39 , 40 ] are a vaccine platform of emerging interest [ 41 , 42 ]. The manufacture and characterization of the PLGA microparticles used in the current study have been previously described in detail [ 29 , 30 , 32 , 36 , 37 ].…”

Section: Introductionmentioning

confidence: 99%

Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine

Harris,

Burkholz,

Herst

et al. 2024

Vaccines

View full text Add to dashboard Cite

The Marburg virus (MARV), the virus responsible for Marburg hemorrhagic fever (MHF), is considered a top-priority pathogen for vaccine development. Recent outbreaks in Equatorial Africa have highlighted the urgency of MARV because of its high fatality rate and historical concerns about potential weaponization. Currently, there are no licensed vaccines for MARV. Existing vaccine candidates rely on attenuated recombinant vesicular stomatitis virus carrying MARV glycoprotein (VSVΔG) or the chimpanzee replication-defective adenovirus 3 vector ChAd3-MARV. Although these platforms provide significant protection in animal models, they face challenges because of their limited thermal stability and the need for cold storage during deployment in resource-poor areas. An alternative approach involves using adjuvanted poly (lactic-co-glycolic acid) (PLGA) microparticles loaded with synthetic peptides representing MHC class I—restricted T cell epitopes. This vaccine platform has demonstrated effectiveness in protecting against SARS-CoV-2 and EBoV disease in animal models and has the advantage of not requiring cold storage and remaining stable at room temperature for over six months. This report outlines the design, manufacturing, and in vivo immunogenicity testing of PLGA microparticle human vaccines designed to prevent Marburg hemorrhagic fever.

show abstract

Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus

Cited by 9 publications

References 87 publications

The quest for nanoparticle-powered vaccines in cancer immunotherapy

The quest for nanoparticle-powered vaccines in cancer immunotherapy

Therapeutic Targeting of MOAP-1 in Cancer: A Systematic Review of Current Approaches and Future Directions

Bioinformatic, Biochemical, and Immunological Mining of MHC Class I Restricted T Cell Epitopes for a Marburg Nucleoprotein Microparticle Vaccine

Contact Info

Product

Resources

About